Half-year report · HY

Period2026-01-01 → 2026-06-30
Filed2026-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥401m2026-01-01 → 2026-06-30Cons.Net sales
Revenue¥579m2025-01-01 → 2025-12-31Cons.Net sales (5-year summary)
Revenue¥251m2025-01-01 → 2025-06-30Cons.Net sales
Operating income−¥954m2026-01-01 → 2026-06-30Cons.Operating income
Operating income−¥1.1bn2025-01-01 → 2025-06-30Cons.Operating income
Ordinary income−¥1.0bn2026-01-01 → 2026-06-30Cons.Ordinary income
Ordinary income−¥2.1bn2025-01-01 → 2025-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.1bn2025-01-01 → 2025-06-30Cons.Ordinary income
Profit before tax−¥1.0bn2026-01-01 → 2026-06-30Cons.Income before income taxes
Profit before tax−¥1.1bn2025-01-01 → 2025-06-30Cons.Income before income taxes
Net income (owners)−¥1.0bn2026-01-01 → 2026-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.2bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent
Net income−¥1.0bn2026-01-01 → 2026-06-30Cons.Profit loss
Net income−¥1.1bn2025-01-01 → 2025-06-30Cons.Profit loss
Total assets¥1.8bnat 2026-06-30Cons.Assets
Total assets¥1.2bnat 2025-12-31Cons.Assets
Total assets¥1.6bnat 2025-06-30Cons.Total assets (5-year summary)
Total liabilities¥2.2bnat 2026-06-30Cons.Liabilities
Total liabilities¥920mat 2025-12-31Cons.Liabilities
Net assets / equity−¥408mat 2026-06-30Cons.Net assets
Net assets / equity¥309mat 2025-12-31Cons.Net assets
Net assets / equity¥1.4bnat 2025-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.1bnat 2026-06-30Cons.Cash and deposits
Cash and deposits¥517mat 2025-12-31Cons.Cash and deposits
Cash & equivalents¥1.1bnat 2026-06-30Cons.Cash and cash equivalents
Cash & equivalents¥517mat 2025-12-31Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2025-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31vCons.Cash and cash equivalents
Operating cash flow−¥915m2026-01-01 → 2026-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥2.2bn2025-01-01 → 2025-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥995m2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥11m2026-01-01 → 2026-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥25m2025-01-01 → 2025-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥16m2025-01-01 → 2025-06-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.5bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥605m2025-01-01 → 2025-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥14m2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-53.132026-01-01 → 2026-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-113.622025-01-01 → 2025-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-55.292025-01-01 → 2025-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio-23.9%at 2026-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio25.1%at 2025-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio85.1%at 2025-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 8
SegmentItemPeriodValue
Drug Discovery Businessreportable segmentsegment profit2026-01-01 → 2026-06-30−¥1.0bn
Drug Discovery Support Businessreportable segmentrevenue2026-01-01 → 2026-06-30¥401m
Drug Discovery Support Businessreportable segmentrevenue external2026-01-01 → 2026-06-30¥401m
Drug Discovery Support Businessreportable segmentsegment profit2026-01-01 → 2026-06-30¥67m
Drug Discovery Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥1.0bn
Drug Discovery Support Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥251m
Drug Discovery Support Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥251m
Drug Discovery Support Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥51m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 442
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任監査法人トーマツ
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)安  田  秀  樹
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)安 場 達 哉
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1InterimDuration251097000JPY
Net sales (5-year summary)InterimDuration401154000JPY
Net sales (5-year summary)Prior1YearDuration579057000JPY
Ordinary income loss (5-year summary)Prior1InterimDuration-1055024000JPY
Ordinary income loss (5-year summary)InterimDuration-1005798000JPY
Ordinary income loss (5-year summary)Prior1YearDuration-2144861000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1InterimDuration-1056054000JPY
Profit loss attributable to owners of parent (5-year summary)InterimDuration-1039782000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration-2171470000JPY
Comprehensive income (5-year summary)Prior1InterimDuration-1086224000JPY
Comprehensive income (5-year summary)InterimDuration-1026125000JPY
Comprehensive income (5-year summary)Prior1YearDuration-2175824000JPY
Net assets (5-year summary)Prior1InterimInstant1391122000JPY
Net assets (5-year summary)InterimInstant-407840000JPY
Net assets (5-year summary)Prior1YearInstant309217000JPY
Total assets (5-year summary)Prior1InterimInstant1635585000JPY
Total assets (5-year summary)InterimInstant1765502000JPY
Total assets (5-year summary)Prior1YearInstant1229648000JPY
Basic earnings loss per share (5-year summary)Prior1InterimDuration-55.29
Basic earnings loss per share (5-year summary)InterimDuration-53.13
Basic earnings loss per share (5-year summary)Prior1YearDuration-113.62
Diluted earnings per share (5-year summary)Prior1InterimDuration-
Diluted earnings per share (5-year summary)InterimDuration-
Diluted earnings per share (5-year summary)Prior1YearDuration-
Equity to asset ratio (5-year summary)Prior1InterimInstant0.851
Equity to asset ratio (5-year summary)InterimInstant-0.239
Equity to asset ratio (5-year summary)Prior1YearInstant0.251
Net cash provided by used in operating activities (5-year summary)Prior1InterimDuration-994641000JPY
Net cash provided by used in operating activities (5-year summary)InterimDuration-914926000JPY
Net cash provided by used in operating activities (5-year summary)Prior1YearDuration-2159363000JPY
Net cash provided by used in investing activities (5-year summary)Prior1InterimDuration-15884000JPY
Net cash provided by used in investing activities (5-year summary)InterimDuration-10593000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YearDuration-25009000JPY
Net cash provided by used in financing activities (5-year summary)Prior1InterimDuration-14006000JPY
Net cash provided by used in financing activities (5-year summary)InterimDuration1503494000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration604711000JPY
Cash and cash equivalents (5-year summary)Prior1InterimInstant1060569000JPY
Cash and cash equivalents (5-year summary)InterimInstant1100479000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant516789000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember20652469
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember21163811
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant20652469
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant21163811
Number of shares heldInterimInstant_No1MajorShareholdersMember613000
Shareholding ratioInterimInstant_No1MajorShareholdersMember0.0296

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2025-12-31pass rounding
balance sheet identityconsolidated 2026-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-12-31pass
statement vs summary · net assetsconsolidated 2026-06-30pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2026-01-01/2026-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2026-01-01/2026-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsconsolidated 2026-06-30pass